• 1
    Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999; 81: 214-218.
  • 2
    Lynch HT, Boland CR, Gong G, et al. Phenotypic and genotypic heterogeneity in the lynch syndrome: Diagnostic, surveillance and management implications. Eur J Hum Genet. 2006; 14: 390-402.
  • 3
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colorectal Cancer Screening. Fort Washington, PA: NCCN; 2011.
  • 4
    Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000; 118: 829-834.
  • 5
    Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome. N Engl J Med. 2006; 354: 261-269.
  • 6
    Linder-Pelz S. Toward a theory of patient satisfaction. Soc Sci Med. 1982; 16: 577-582.
  • 7
    Collins VR, Meiser B, Ukoumunne OC, Gaff C, St John DJ, Halliday JL. The impact of predictive genetic testing for hereditary nonpolyposis colorectal cancer: Three years after testing. Genet Med. 2007; 9: 290-297.
  • 8
    Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kääriäinen H. Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): A prospective follow-up study. Int J Cancer. 2001; 93: 608-611.
  • 9
    Gritz ER, Peterson SK, Vernon SW, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2005; 23: 1902-1910.
  • 10
    Keller M, Jost R, Haunstetter CM, et al. Psychosocial outcome following genetic risk counselling for familial colorectal cancer. A comparison of affected patients and family members. Clin Genet. 2008; 74: 414-424.
  • 11
    Carlsson C, Nilbert M. Living with hereditary non-polyposis colorectal cancer; experiences from and impact of genetic testing. J Genet Couns. 2007; 16: 811-820.
  • 12
    Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann Intern Med. 2011; 155: 69-79.
  • 13
    Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010; 12: 93-104.
  • 14
    Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for lynch syndrome in the general population. Cancer Prev Res (Phila). 2011; 4: 9-22.
  • 15
    Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. Health Psychol. 1991; 10: 259-267.
  • 16
    Wu JM, Fulton RG, Amundsen CL, Knight SK, Kuppermann M. Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg. 2011; 17: 184-189.
  • 17
    Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986; 5: 1-30.
  • 18
    Kuppermann M, Nease RFJr, Gates E, et al. How do women of diverse backgrounds value prenatal testing outcomes? Prenat Diagn. 2004; 24: 424-429.